Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Small Cell Lung Carcinoma 2Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Oligodendroglioma 1Neoplasm Metastasis 1Malignant Solid Tumor 1Glioblastoma 1Brain Neoplasms 1Astrocytoma 1

Interventions

Temozolomide 73Bevacizumab 58Radiotherapy 40Radiosurgery 28Carboplatin 23Nivolumab 17Etoposide 17Cisplatin 17pembrolizumab 16Irinotecan 16Ipilimumab 15Magnetic Resonance Spectroscopy 14Erlotinib Hydrochloride 14Cyclophosphamide 14Carmustine 14Pemetrexed 13Topotecan 10Surgical Procedures, Operative 10Capecitabine 10Lapatinib 9Filgrastim 9Trastuzumab 8Thalidomide 8Sunitinib 8Paclitaxel 8Lomustine 8Aminolevulinic Acid 8encorafenib 7binimetinib 7Vincristine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Brain Neoplasms × etirinotecan pegol × Clear all
NCT02312622 2023-12-12

Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer

Stanford University

Phase 2 Completed
27 enrolled 19 charts
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡